top of page

PRODUCTS
- CANCER PRE-SCREENING
- BRCA GERMLINE
TECH & SCIENCE
CLINICAL TRIALS
- THE RAINBOW STUDY
- THE PINK STUDY
ABOUT
LET'S CONNECT
INVEST

All Posts
Technology
Early Detection
Screening
Innovation
Breath Samples
Research
People
Values
Goals
Process
VOC
AI
Expertise
Wellbeing
Team
Mission
Dogs
Non Invasive testing
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
Privacy
Data
Regulation

All Posts

abstract illustration of SpotitEarly's innovation in cancer diagnostics

abstract illustration of SpotitEarly's innovation in cancer diagnostics

The Future of Cancer Detection: SpotitEarly's Innovation Pipeline and Technological Breakthroughs

SpotitEarly Team

12 hours ago4 min read

Abstract illustration representing spotitearly innovation in the cancer detection industry

Abstract illustration representing spotitearly innovation in the cancer detection industry

Navigating the Cancer Detection Revolution: Industry Trends and How SpotitEarly is Leading the Change

SpotitEarly Team

Sep 244 min read

Protecting Patient Privacy: SpotitEarly’s Approach to Healthcare Data Security and HIPAA Compliance

Protecting Patient Privacy: SpotitEarly’s Approach to Healthcare Data Security and HIPAA Compliance

Protecting Patient Privacy: SpotitEarly’s Approach to Healthcare Data Security and HIPAA Compliance

SpotitEarly Team

Sep 173 min read

Abstract illustration comparing traditional cancer screening, liquid biopsies, and SpotitEarly’s breath test

Abstract illustration comparing traditional cancer screening, liquid biopsies, and SpotitEarly’s breath test

Cancer Screening Today: Traditional Tests, Liquid Biopsies, and SpotitEarly’s Breath-Based Breakthrough

Early Detection

SpotitEarly Team

Sep 105 min read

Illustration of dog working and detecting cancer at a SpotitEarly lab

Illustration of dog working and detecting cancer at a SpotitEarly lab

Inside the Training and Life of SpotitEarly’s Cancer Detection Dogs

SpotitEarly Team

Apr 185 min read

Illustration of SpotitEarly's revolutionary breath analysis for cancer detection

Illustration of SpotitEarly's revolutionary breath analysis for cancer detection

Why Breath Analysis Is Revolutionizing Early Cancer Detection

SpotitEarly Team

Apr 114 min read

Illustration of Dr. Len Lichtenfeld, CMO of SpotitEarly

Illustration of Dr. Len Lichtenfeld, CMO of SpotitEarly

Dr. Len Lichtenfeld Joins SpotitEarly as Chief Medical Officer to Advance Early Cancer Detection

SpotitEarly Team

Apr 43 min read

Illustration of LUCID, SpotitEarly's bio-hybrid cancer detection technology

Illustration of LUCID, SpotitEarly's bio-hybrid cancer detection technology

Inside LUCID: SpotitEarly’s Bio-Hybrid Platform Transforming Early Cancer Detection

SpotitEarly Team

Mar 283 min read

Illustration of SpotitEarly research and innovation

Illustration of SpotitEarly research and innovation

The Rainbow Study: Validating SpotitEarly’s Multi-Cancer Detection Method

SpotitEarly Team

Mar 214 min read

Illustration of SpotitEarly's transformative AI cancer detection technology

Illustration of SpotitEarly's transformative AI cancer detection technology

The transformative role of AI in SpotitEarly’s cancer screening process

SpotitEarly Team

Mar 143 min read

Illustration of SpotitEarly's Dogs ability to detect cancer

Illustration of SpotitEarly's Dogs ability to detect cancer

The Science Behind Dogs’ Ability to Detect Cancer Through Scent

SpotitEarly Team

Mar 74 min read

Illustration of SpotitEarly innovative early cancer detection work

Illustration of SpotitEarly innovative early cancer detection work

Discover SpotitEarly’s Groundbreaking Work in Early Cancer Detection

SpotitEarly Team

Feb 283 min read

Illustration of Udi Bobrovsky, SpotitEarly COO

Illustration of Udi Bobrovsky, SpotitEarly COO

The people behind healthcare innovation: Interview with Udi Bobrovsky, COO of SpotitEarly

SpotitEarly Team

Feb 211 min read

SpotitEarly at-home cancer screening test

SpotitEarly at-home cancer screening test

The journey of a SpotitEarly breath sample: From ordering to results

SpotitEarly Team

Feb 143 min read

How SpotitEarly Partners with Hospitals and Researchers to Drive Breakthrough Cancer Detection

How SpotitEarly Partners with Hospitals and Researchers to Drive Breakthrough Cancer Detection

How SpotitEarly Partners with Hospitals and Researchers to Drive Breakthrough Cancer Detection

SpotitEarly Team

Feb 73 min read

Meet the SpotitEarly Team: Innovators Behind Breath-Based Cancer Detection

Meet the SpotitEarly Team: Innovators Behind Breath-Based Cancer Detection

Meet the SpotitEarly Team: Innovators Behind Breath-Based Cancer Detection

SpotitEarly Team

Jan 316 min read

SpotitEarly’s Mission: Revolutionizing Global Cancer Detection Through Breath Analysis and AI

SpotitEarly’s Mission: Revolutionizing Global Cancer Detection Through Breath Analysis and AI

SpotitEarly’s Mission: Revolutionizing Global Cancer Detection Through Breath Analysis and AI

SpotitEarly Team

Jan 244 min read

DISCLAIMER

The securities referred to in this website may be sold only to accredited investors, which for natural persons, are investors who meet certain minimum annual income or net worth thresholds. These securities are being offered in reliance on an exemption from the registration requirements of the Securities Act and are not required to comply with specific disclosure requirements that apply to registration under the Securities Act. The Securities and Exchange Commission has not passed on the
merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials. The securities are subject to legal restrictions on transfer and resale and investors should not assume that they will be able to resell their securities. Investing in securities involves risk, and investors should be able to bear the loss of their investment. The securities referred to in this website are being offered only by means of the Company’s Private Offering Memorandum

SAFE HARBOR STATEMENT

Matters discussed in this website contain forward-looking statements. When used in this update, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with our history of losses and our need to raise additional financing, the acceptance of our products and technology in the marketplace, our ability to demonstrate the commercial viability of our products and technology and our need to increase the size of our organization. Further information on the Company's risk factors is contained in the Company's Private Offering Memorandum. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason except as may be required under applicable law.

BIO-AI HYBRID PLATFORM
THE CANINE ADVANTAGE
BREATH SCIENCE
CANCER PRE-SCREENING
BRCA GERMLINE
THE RAINBOW STUDY
CANINE WELFARE
OUR STORY
TEAM & INVESTORS
LET'S CONNECT

ALL RIGHTS RESERVED,
SPOTITEARLY 2025

TERMS & CONDITIONS

CLIA registration: 99D2307137

USPTO patent pending: WO2023239834A1

hello@SpotitEarly.com

ALL RIGHTS RESERVED,
SPOTITEARLY 2025

SpotitEarly tests are not intended to replace current screening procedures, but rather to be used as an additional pre-screening layer to complement preventative protocols already in place.

The SpotitEarly tests have not been approved by the Food and Drug Administration (FDA) and are currently under development and validation.

Be the First to Know

Stay up to date with media features, clinical milestones, and where to find us next.

Email

PRODUCTS
- CANCER PRE-SCREENING
- BRCA GERMLINE
TECH & SCIENCE
CLINICAL TRIALS
- THE RAINBOW STUDY
- THE PINK STUDY
ABOUT
LET'S CONNECT
INVEST

bottom of page